The AVL9 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This model provides a loss-of-function system for AVL9, generated through CRISPR/Cas9-mediated gene disruption. The polyclonal format offers a heterogeneous knockout pool, minimizing clonal selection bias and enabling robust population-level functional studies.
The A-549 cell line, established from a 58-year-old Caucasian male with lung adenocarcinoma, serves as a widely used epithelial model for human lung cancer. These cells are integral to research in cancer biology, respiratory diseases, and drug development, owing to their well-characterized signaling networks and relevance to adenocarcinoma pathology.
AVL9 is implicated in the regulation of cell migration and invasion through its involvement in vesicle-mediated transport and cytoskeletal dynamics. Acting downstream of EGF, TGF-??, and integrin signaling, AVL9 facilitates the recycling of integrins and membrane components to the leading edge, thereby promoting focal adhesion turnover and actin reorganization. This process engages key effectors including FAK, Src, Rho GTPases (Rac1, Cdc42, RhoA), and matrix metalloproteinases (MMPs), while AVL9 associates with actin, vimentin, and vesicle trafficking proteins. The coordinated activity of downstream pathway components such as ROCK, PAK, talin, and paxillin drives membrane protrusion and sustained cell motility.
In the context of A-549 lung adenocarcinoma cells, disruption of AVL9 compromises the machinery essential for migration and invasion, leading to reduced focal adhesion dynamics and cytoskeletal remodeling. This attenuated motile phenotype makes the knockout cells a valuable platform for investigating the mechanisms underlying metastatic dissemination and for evaluating therapeutic strategies aimed at inhibiting cancer cell motility.
The AVL9 Knockout A-549 Polyclonal Cells are suitable for a range of experimental approaches, including wound healing and transwell invasion assays to assess migratory and invasive capacity, immunofluorescence staining for F-actin to visualize cytoskeletal structures, and phospho-signaling analyses to probe FAK/Src/Rho GTPase pathways. Additional applications encompass western blotting and RT-qPCR for gene expression validation, co-immunoprecipitation for interaction studies, and live-cell imaging to monitor dynamic migration processes. For further details, please contact Ascent Research.
